Resultados da busca - Dong‐Hyeon Kim
- Mostrando 1 - 12 resultados de 12
-
1
-
2
-
3
4-1BB Engagement Costimulates NKT Cell Activation and Exacerbates NKT Cell Ligand-Induced Airway Hyperresponsiveness and Inflammation por Dong‐Hyeon Kim, Woo‐Sung Chang, Yoon Sook Lee, Kyoo‐A Lee, Yoon‐Keun Kim, Byoung S. Kwon, Chang‐Yuil Kang
Publicado em 2008Artigo -
4
-
5
Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial por Geert D’Haens, Walter Reinisch, Stefan Schreiber, Fraser Cummings, Peter M. Irving, Byong Duk Ye, Dong‐Hyeon Kim, Sang-Wook Yoon, Shomron Ben–Horin
Publicado em 2023Artigo -
6
Fate of Escherichia coli O157:H7 and bacterial diversity in corn silage contaminated with the pathogen and treated with chemical or microbial additives por Ibukun M Ogunade, Yun Jiang, Dong Hyeon Kim, Andres A Pech-Cervantes, K.G. Arriola, D. Vyas, Z.G. Weinberg, Kwangcheol Casey Jeong, A.T. Adesogan
Publicado em 2016Artigo -
7
Exogenous fibrolytic enzymes and recombinant bacterial expansins synergistically improve hydrolysis and in vitro digestibility of bermudagrass haylage por Andres A Pech-Cervantes, Muhammad Ishaq, Ibukun M Ogunade, Yun Jiang, Dong Hyeon Kim, Claudio F. González, Timothy J. Hackmann, André Soares de Oliveira, D. Vyas, A.T. Adesogan
Publicado em 2019Artigo -
8
Dynamic Changes in Fecal Microbial Communities of Neonatal Dairy Calves by Aging and Diarrhea por Eun Tae Kim, Sang-Jin Lee, Tae-Yong Kim, Hyo Gun Lee, Md Atikur Rahman, Bon‐Hee Gu, Dong Hyeon Kim, Beom-Young Park, Jun-Kyu Son, Myunghoo Kim
Publicado em 2021Artigo -
9
Comparative Efficacy of Subcutaneous and Intravenous Infliximab and Vedolizumab for Maintenance Treatment of TNF-naive Adult Patients with Inflammatory Bowel Disease: A Systematic... por Laurent Peyrin–Biroulet, Peter Bossuyt, Dominik Bettenworth, Edward V. Loftus, Suzanne I. Anjie, Geert D’Haens, Masayuki Saruta, Perttu Arkkila, Henry S. Park, Dughyun Choi, Dong‐Hyeon Kim, Walter Reinisch
Publicado em 2024Revisão -
10
Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis por Laurent Peyrin–Biroulet, Perttu Arkkila, Alessandro Armuzzi, Silvio Danese, Jordi Guardiola, Jørgen Jahnsen, Charlie W. Lees, Édouard Louis, Milan Lukáš, Walter Reinisch, Xavier Roblin, Minyoung Jang, Han Geul Byun, Dong‐Hyeon Kim, Sung Jeong Lee, Raja Atreya
Publicado em 2022Revisão -
11
Development and Validation of a Deep Learning–based Automatic Detection Algorithm for Active Pulmonary Tuberculosis on Chest Radiographs por Eui Jin Hwang, Sunggyun Park, Kwang-Nam Jin, Jung Im Kim, So Young Choi, Jong Hyuk Lee, Jin Mo Goo, Jaehong Aum, Jae‐Joon Yim, Chang Min Park, Dong Hyeon Kim, Woo Woo, Choi Choi, Inpyeong Hwang, Yong Sub Song, Lim Lim, Kim Kim, Jae Yeon Wi, S. Oh, Mi‐Jin Kang
Publicado em 2018Artigo -
12
Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemia por Ji Eun Shin, Soo‐Hyun Kim, Mingyu Kong, Hwa-Ryeon Kim, Sungmin Yoon, Kyung‐Mi Kee, Jung Ah Kim, Dong Hyeon Kim, So Yeon Park, Jae Hyung Park, Hongtae Kim, Kyoung Tai No, Han‐Woong Lee, Heon Yung Gee, Seunghee Hong, Kun‐Liang Guan, Jae‐Seok Roe, Hyunbeom Lee, Dong‐Wook Kim, Hyun Woo Park
Publicado em 2023Artigo
Ferramentas de busca:
Assuntos relacionados
Biology
Medicine
Genetics
Internal medicine
Bacteria
Biochemistry
Food science
Microbiology
Chemistry
Disease
Gastroenterology
Immunology
Infliximab
Lactobacillus
Ulcerative colitis
16S ribosomal RNA
Bacteroidetes
Chromatography
Clinical trial
Dry matter
Ecology
Feces
Fermentation
Gene
Inflammatory bowel disease
Lactic acid
Organic chemistry
Pathology
Randomized controlled trial
Vedolizumab